What is First Tracks Biotherapeutics, Inc.'s (TRAX) StockRank?

MoatMap's StockRank for First Tracks Biotherapeutics, Inc. (TRAX) is 10/100, with a Strong Sell signal. This is a composite score combining Quality (29), Value (37), and Momentum (28) factor ranks across MoatMap's 20,000+ stock universe.

Does First Tracks Biotherapeutics, Inc. have an economic moat?

First Tracks Biotherapeutics, Inc. (TRAX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is First Tracks Biotherapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for First Tracks Biotherapeutics, Inc. (TRAX) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is First Tracks Biotherapeutics, Inc. in?

First Tracks Biotherapeutics, Inc. (TRAX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TRAX

STRONG SELLREMOVE

First Tracks Biotherapeutics, Inc. · Healthcare · United States · $552M · Avg Vol: $9M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

First Tracks Biotherapeutic is an early-stage biotechnology company. It lacks commercial-stage assets, predictable cash flows, and a proven business model, making it a speculative bet rather than a high-conviction quality compounder.

COMPANY DESCRIPTION

First Tracks Biotherapeutics is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary platform focuses on engineering highly selective monoclonal antibodies and cell therapies designed to modulate the immune microenvironment. Its competitive moat is anchored by a robust pipeline of early-stage candidates and proprietary intellectual property in immune-oncology pathways.

FINANCIAL SUMMARY (USD)

Year	2023	2024
Revenue	0	0
EPS	-3.05	—
Shares	35M	35M
Debt	18M	16M
Equity	410M	392M
Op CF	-93M	-126M
Inv CF	145M	95M
Fin CF	-87M	118M

PRICE (1M)-2.2%

SMA 50SMA 200

$17.42

RSI (14)

54.9

SCORE BREAKDOWN

Quality

ROIC

-44.6%15.9

ROE

—N/A

GP/Assets

-31.6%3.0

Op. Margin

0.0%40.4

FCF/Assets

—N/A

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

8.74x84.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.8x66.5

P/FCF

—N/A

P/B

2.4x48.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+33%44.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$552M

P/E (Forward)

-5.6x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRAX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TRAX	First Tracks Biotherapeutics, Inc.(you)	$552M	10	STRONG SELL
EDIT	Editas Medicine, Inc.	$526M	10	STRONG SELL
PROK	ProKidney Corp.	$547M	11	STRONG SELL
EIKN	Eikon Therapeutics, Inc.	$558M	13	STRONG SELL
ARVN	Arvinas, Inc.	$570M	14	STRONG SELL
ALT	Altimmune, Inc.	$597M	6	STRONG SELL
OCGN	Ocugen, Inc.	$477M	7	STRONG SELL
FBRX	Forte Biosciences, Inc.	$425M	9	STRONG SELL
FULC	Fulcrum Therapeutics, Inc.	$454M	13	STRONG SELL
BBOT	BridgeBio Oncology Therapeutics, Inc.	$708M	12	STRONG SELL

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%

First Tracks Biotherapeutics, Inc. (TRAX) — Stock Score Summary

First Tracks Biotherapeutics, Inc. (TRAX) has a MoatMap StockRank of 10/100 based on Quality (29/100), Value (37/100), and Momentum (28/100) factor scores. The current signal is STRONG SELL. First Tracks Biotherapeutic is an early-stage biotechnology company. It lacks commercial-stage assets, predictable cash flows, and a proven business model, making it a speculative bet rather than a high-conviction quality compounder.

Key Financial Metrics

Price	$17.42
Market Cap	$552M
P/E (Forward)	-5.62
Price/Book	2.39
Return on Invested Capital	-44.6%
Gross Margin	0.0%
Operating Margin	0.0%

First Tracks Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is First Tracks Biotherapeutics, Inc.’s (TRAX) StockRank?: MoatMap’s StockRank for First Tracks Biotherapeutics, Inc. (TRAX) is 10/100, with a Strong Sell signal. It is a composite of Quality (29), Value (37), and Momentum (28) factor ranks across MoatMap’s 20,000+ stock universe.
Does First Tracks Biotherapeutics, Inc. have an economic moat?: First Tracks Biotherapeutics, Inc. (TRAX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is First Tracks Biotherapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for First Tracks Biotherapeutics, Inc. (TRAX) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is First Tracks Biotherapeutics, Inc. in?: First Tracks Biotherapeutics, Inc. (TRAX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).